Comparative Pharmacology
Head-to-head clinical analysis: CERETEC versus MIRALUMA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CERETEC versus MIRALUMA.
CERETEC vs MIRALUMA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Technetium-99m exametazime (Ceretec) is a lipophilic radiopharmaceutical that crosses the blood-brain barrier and is taken up by brain tissue in proportion to regional cerebral blood flow. Once inside cells, it undergoes intracellular conversion to a hydrophilic form, trapping it in the brain and allowing SPECT imaging.
MIRALUMA (garadacimab) is a monoclonal antibody that binds to activated factor XII (FXIIa) and inhibits its activity, thereby blocking the contact activation pathway of the coagulation cascade. This prevents the generation of bradykinin, reducing vascular permeability and swelling in hereditary angioedema (HAE).
555-740 MBq (15-20 mCi) intravenously as a single dose for SPECT imaging.
MIRALUMA (mirvetuximab soravtansine) is administered intravenously at 6 mg/kg adjusted ideal body weight (AIBW) once every 3 weeks until disease progression or unacceptable toxicity.
None Documented
None Documented
Terminal: 6 hours (range 4–8 h); clinical: supports twice-daily dosing in nuclear medicine studies.
20 hours; prolonged to 30-40 hours in renal impairment requiring dose adjustment
Renal: 40% unchanged; biliary/fecal: 60% (as metabolites and parent compound).
90% renal as unchanged drug; 10% biliary/fecal
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical